- While first generation chimeric antigen receptor T (CAR-T) cell therapy has shown impressive results curing blood cancers at significantly higher rates than previous therapies, issues such as high costs, complexity of treatment, and potential life threatening side effects have limited their use.
- Next generation CAR-T cell therapy made using pluripotent stem cells seeks to maintain first generation CAR-T cell therapy’s efficacy while reducing the issues that have limited adoption
- If successful, these advances in stem cell based CAR-T cell therapy could boost adoption and expand the addressable market for CAR-T therapies into earlier line therapies and even into solid tumors while reducing the financial burden of the treatment and improving its safety
Click on the PDF to read the full report.